Thrombosis in Paroxysmal Nocturnal Hemoglobinuria – insights into the role of complement in thrombosis

Thrombosis Research

Volumn 125, Issue , 2010, Pages S106-S107

  Weitz, Ilene C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Complement; D dimers; Thrombosis; Tissue factor microparticles

Indexed keywords

COMPLEMENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ARTICLE; HUMAN; IMMUNOLOGY; METABOLISM; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; THROMBOSIS;

COMPLEMENT SYSTEM PROTEINS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; THROMBOSIS;

EID: 77955494561     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70026-8     Document Type: Article

References (13)

1. Hill, A, Rother, RP, Risitano, AM, Cole, DS, Cullen, MJ, Richards, SJ, et al. Blockade of intravascular hemolysis in PNH with the terminal complement inhibitor eculizumab unmasks low-level hemolysis potentially occurring through C3 opsonization. Blood, 290a, 2006 (Abstract 972).
2. Nishimura, J-I, Kanakura, Y, Ware, RE, Shichishima, T, Nakakuma, H, Ninomiya, H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 83 (2004), 193–207.
3. Hillmen, P, Lewis, SM, Bessler, M, Luzzatto, L, Dacie, JV, Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333 (1995), 1253–1258.
4. Moyo, VM, Mukhina, GL, Garrett, ES, Brodsky, RA, Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 126 (2004), 133–138.
5. Parker, C, Omine, M, Richards, S, Nishimura, J, Bessler, M, Ware, R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005), 3699–3709.
6. Wiedmer, T, Hall, SE, Ortel, TL, Kane, WH, Rosse, WF, Sims, PJ, Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 82 (1993), 1192–1196.
7. Weitz, IC, Rochanda, L, Razavi, P, Liebman, H, Effect of eculizumab therapy on thrombocytopenia in patients with PNH. Haematologica(suppl), 2009 June abstract 1094.
8. Simak, J, Holada, K, Risitano, AM, Zivny, JH, Young, NS, Vostal, JG, Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol 125:6 (2004), 804–813.
9. Helley, D, Peffault de Latour, R, Pocher, R, Rodrigues, CA, Matheron, J, Galy-Fauroux, I, et al. Coagulation activation and endothelial dysfunction in patients with paroxysmal nocturnal hemoglobinuria. Beneficial effect of eculizumab treatment. J Thromb Haemost, 2009 July abstract 351.
10. Hillmen, P, Young, NS, Schubert, J, Brodsky, RA, Socié, G, Muus, P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 (2006), 1233–1243.
11. Brodsky, RA, Young, NS, Antonioli, E, Risitano, AM, Schrezenmeier, H., Schubert, J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111 (2008), 1840–1847.
12. Hillmen, P, Muus, P, Dührsen, U, Risitano, AM, Schubert, J, Luzzatto, L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 (2007), 4123–4128.
13. Weitz, IC, Ghods, M, Rochanda, L, Prazavi, P, Zwicker, J, Furie, B, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH. ASH Annual Meeting Abstracts, 112, 2008, 407.